Marn Pernat Andreja, Medved Bojan, Gubenšek Jakob, Premru Vladimir, Knap Bojan, Buturovic-Ponikvar Jadranka, Ponikvar Rafael
University Medical Center Ljubljana, Department of Nephrology, Ljubljana, Slovenia.
Ther Apher Dial. 2016 Jun;20(3):251-5. doi: 10.1111/1744-9987.12432.
We proposed a combination of convective and diffusive transport mechanisms as high cut-off (HCO) post-dilution hemodiafiltration dialysis technique to optimize serum immunoglobulin free light chains (FLCs) removal which may improve dialysis dependent renal failure in patients with multiple myeloma. To reduce bleeding risk regional citrate anticoagulation was successfully used for the first 7 h followed by 1 h anticoagulant-free hemodiafiltration to avoid citrate accumulation. We retrospectively assessed the effect of FLCs reduction on the renal outcome of 28 patients treated with 133 citrate extended post-dilution HCO (Theralite 2100; Gambro, Lund, Sweden) hemodiafiltration sessions between 2010 and 2016. Renal recovery was demonstrated in 61% of all patients. Twenty-three patients achieved more than 50% reduction of FLCs concentrations and 88% of those became dialysis independent. Our experience supports the extended citrate HCO hemodiafiltration as a good treatment strategy that enable a sustained reduction in serum FLCs concentration and recovery of renal function.
我们提出将对流和扩散传输机制相结合,作为高通量(HCO)后稀释血液透析滤过技术,以优化血清免疫球蛋白游离轻链(FLC)的清除,这可能改善多发性骨髓瘤患者的透析依赖性肾衰竭。为降低出血风险,最初7小时成功采用局部枸橼酸抗凝,随后1小时进行无抗凝剂血液透析滤过,以避免枸橼酸蓄积。我们回顾性评估了2010年至2016年间,28例接受133次枸橼酸延长后稀释HCO(Theralite 2100;瑞典隆德甘布罗公司)血液透析滤过治疗的患者,FLC降低对肾脏结局的影响。61%的患者实现了肾脏恢复。23例患者的FLC浓度降低超过50%,其中88%的患者不再依赖透析。我们的经验支持延长枸橼酸HCO血液透析滤过作为一种良好的治疗策略,可使血清FLC浓度持续降低并恢复肾功能。